Adenoviral delivery of vegf promotes short term angiogenic effect

Matthew J. Gounis, Baruch B. Lieber, Keith A Webster, M. Grazia Spiga, Nanette Bishopric, Ajay K. Wakhloo

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

A longitudinal in vivo study has been completed to evaluate the angiogenic benefit of an adenoviral vector used to express vascular endothelial growth factor (VEGF 165). Subsequently, numerous methods of therapeutic angiogenesis, including different gene delivery vehicles as well as the route of administration of these vectors, have been studied using angiographic time-intensity data. Mathematical modeling of these data provides indices of the formation and function of new vessel growth in response to the treatment modality. The angiographic and immunohistological results demonstrate that adenoviral (Ad) delivery of VEGF promotes a rapid angiogenic effect within the first week of treatment. However, this effect is not sustained and returns to control levels within three weeks. These results support the conclusion that Ad mediated therapeutic angiogenesis may not provide long term benefit.

Original languageEnglish
Title of host publicationProceedings of the 2005 Summer Bioengineering Conference
Pages709-710
Number of pages2
Volume2005
StatePublished - Dec 1 2005
Event2005 Summer Bioengineering Conference - Vail, CO, United States
Duration: Jun 22 2005Jun 26 2005

Other

Other2005 Summer Bioengineering Conference
CountryUnited States
CityVail, CO
Period6/22/056/26/05

Fingerprint

Level control
Genes
Intercellular Signaling Peptides and Proteins

ASJC Scopus subject areas

  • Engineering(all)

Cite this

Gounis, M. J., Lieber, B. B., Webster, K. A., Spiga, M. G., Bishopric, N., & Wakhloo, A. K. (2005). Adenoviral delivery of vegf promotes short term angiogenic effect. In Proceedings of the 2005 Summer Bioengineering Conference (Vol. 2005, pp. 709-710)

Adenoviral delivery of vegf promotes short term angiogenic effect. / Gounis, Matthew J.; Lieber, Baruch B.; Webster, Keith A; Spiga, M. Grazia; Bishopric, Nanette; Wakhloo, Ajay K.

Proceedings of the 2005 Summer Bioengineering Conference. Vol. 2005 2005. p. 709-710.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Gounis, MJ, Lieber, BB, Webster, KA, Spiga, MG, Bishopric, N & Wakhloo, AK 2005, Adenoviral delivery of vegf promotes short term angiogenic effect. in Proceedings of the 2005 Summer Bioengineering Conference. vol. 2005, pp. 709-710, 2005 Summer Bioengineering Conference, Vail, CO, United States, 6/22/05.
Gounis MJ, Lieber BB, Webster KA, Spiga MG, Bishopric N, Wakhloo AK. Adenoviral delivery of vegf promotes short term angiogenic effect. In Proceedings of the 2005 Summer Bioengineering Conference. Vol. 2005. 2005. p. 709-710
Gounis, Matthew J. ; Lieber, Baruch B. ; Webster, Keith A ; Spiga, M. Grazia ; Bishopric, Nanette ; Wakhloo, Ajay K. / Adenoviral delivery of vegf promotes short term angiogenic effect. Proceedings of the 2005 Summer Bioengineering Conference. Vol. 2005 2005. pp. 709-710
@inproceedings{7f7f5f5321814a1e9aa43e745be9847b,
title = "Adenoviral delivery of vegf promotes short term angiogenic effect",
abstract = "A longitudinal in vivo study has been completed to evaluate the angiogenic benefit of an adenoviral vector used to express vascular endothelial growth factor (VEGF 165). Subsequently, numerous methods of therapeutic angiogenesis, including different gene delivery vehicles as well as the route of administration of these vectors, have been studied using angiographic time-intensity data. Mathematical modeling of these data provides indices of the formation and function of new vessel growth in response to the treatment modality. The angiographic and immunohistological results demonstrate that adenoviral (Ad) delivery of VEGF promotes a rapid angiogenic effect within the first week of treatment. However, this effect is not sustained and returns to control levels within three weeks. These results support the conclusion that Ad mediated therapeutic angiogenesis may not provide long term benefit.",
author = "Gounis, {Matthew J.} and Lieber, {Baruch B.} and Webster, {Keith A} and Spiga, {M. Grazia} and Nanette Bishopric and Wakhloo, {Ajay K.}",
year = "2005",
month = "12",
day = "1",
language = "English",
isbn = "0974249211",
volume = "2005",
pages = "709--710",
booktitle = "Proceedings of the 2005 Summer Bioengineering Conference",

}

TY - GEN

T1 - Adenoviral delivery of vegf promotes short term angiogenic effect

AU - Gounis, Matthew J.

AU - Lieber, Baruch B.

AU - Webster, Keith A

AU - Spiga, M. Grazia

AU - Bishopric, Nanette

AU - Wakhloo, Ajay K.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - A longitudinal in vivo study has been completed to evaluate the angiogenic benefit of an adenoviral vector used to express vascular endothelial growth factor (VEGF 165). Subsequently, numerous methods of therapeutic angiogenesis, including different gene delivery vehicles as well as the route of administration of these vectors, have been studied using angiographic time-intensity data. Mathematical modeling of these data provides indices of the formation and function of new vessel growth in response to the treatment modality. The angiographic and immunohistological results demonstrate that adenoviral (Ad) delivery of VEGF promotes a rapid angiogenic effect within the first week of treatment. However, this effect is not sustained and returns to control levels within three weeks. These results support the conclusion that Ad mediated therapeutic angiogenesis may not provide long term benefit.

AB - A longitudinal in vivo study has been completed to evaluate the angiogenic benefit of an adenoviral vector used to express vascular endothelial growth factor (VEGF 165). Subsequently, numerous methods of therapeutic angiogenesis, including different gene delivery vehicles as well as the route of administration of these vectors, have been studied using angiographic time-intensity data. Mathematical modeling of these data provides indices of the formation and function of new vessel growth in response to the treatment modality. The angiographic and immunohistological results demonstrate that adenoviral (Ad) delivery of VEGF promotes a rapid angiogenic effect within the first week of treatment. However, this effect is not sustained and returns to control levels within three weeks. These results support the conclusion that Ad mediated therapeutic angiogenesis may not provide long term benefit.

UR - http://www.scopus.com/inward/record.url?scp=33646582615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646582615&partnerID=8YFLogxK

M3 - Conference contribution

AN - SCOPUS:33646582615

SN - 0974249211

SN - 9780974249216

VL - 2005

SP - 709

EP - 710

BT - Proceedings of the 2005 Summer Bioengineering Conference

ER -